Third quarter results highlight strong operational performance across key value drivers: YUPELRI ® (revefenacin) net sales of $62.2 million , recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 2024 1 CYPRESS enrollment in-line with expectations, with timelines on track TRELEGY net sales increased 17%, to $789 million , as reported by GSK: Q4 sales of at least ~$260 million needed to earn $25 million milestone 2 Q4 sales of at least ~$610 million needed to earn $50 million milestone 2 Board of Directors announces initiatives to unlock shareholder value and enhance corporate governance DUBLIN , Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc.
("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today reported financial and operational results for the third quarter of 2024 and announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value. Reflecting on the quarter's operational performance, Rick Winningham , Theravance Biopharma CEO commented, "Through our collaboration with Viatris, we achieved a strong quarter for YUPELRI demand and made progress on recent mix-related pricing headwinds, therein driving quarterly net sales to an all-time high. We believe we are well positioned to build on recent momentum and achieve continued YUPELRI growth, while continuing to pay careful attention to our cost structure.
" He continued, "In addition, we are pleased with the progress we made in CYPRESS.